Radius prices $300M notes offering

Radius Health Inc. (NASDAQ:RDUS) raised $300 million through the sale of 3% senior convertible notes due Sept.1, 2024. The notes have an initial conversion price of $48.81, which is a 21% premium to the company's close of $40.46 on Monday, when it proposed the offering after market hours. JPMorgan, Morgan Stanley, Citigroup and Leerink are underwriters.

In May, Radius launched Tymlos abaloparatide-SC after FDA approved the drug in late April to treat postmenopausal women with osteoporosis at high risk for fracture. For the three months ending June 30, the company reported about $1 million in net product revenue. Tymlos is a subcutaneous peptide analog of parathyroid hormone-related protein (PTHrP) (see BioCentury Extra, April 28)...